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A B S T R A C T

A typical DYT1 dystonia is caused by a heterozygous GAG deletion (c.907–909) in the TOR1A gene (ΔE, p.Glu303del) and the pathogenesis is not clear. In this study,
human induced pluripotent stem cell (hiPSC) lines carrying the heterozygous or homozygous GAG deletion in TOR1A gene were generated by genetic modification of
a healthy hiPSC line (WTC11, UCSFi001-A). These hiPSC lines showed the normal stem cell morphology and karyotype, expressed the same pluripotency markers as
their parental line, and had the capacity to differentiate into three germ layers, providing a valuable resource in determining the pathogenesis of human DYT1
dystonia.

(continued )

1. Resource Table
Unique stem cell lines identifier
Institution
Contact information of the reported
cell line distributor
Type of cell lines
Origin
Additional origin info (applicable for
human ESC or iPSC)
Cell Source
Method of reprogramming
Clonality
Evidence of the reprogramming
transgene loss (including genomic
copy if applicable)
Cell culture system used
Type of Genetic Modification
Associated disease
Gene/locus
Multiline rationale
Method of modification/site-specific
nuclease used
Site-specific nuclease (SSN) delivery
method
All genetic material introduced into
the cells

ULLi002-A-49
ULLi002-A-51
University of Louisiana at Lafayette, LA USA
Baojin Ding (Baojin.Ding@Louisiana.edu)
iPSC
Human
Age: 30 YR
Sex: Male
Ethnicity: Asian
Skin fibroblasts.
N/A
Clonal
RT/q-PCR

Unique stem cell lines identifier
Analysis of the nuclease-targeted
allele status
Method of the off-target nuclease
activity surveillance
Name of transgene
Eukaryotic selective agent resistance
(including inducible/gene
expressing cell-specific)
Inducible/constitutive system details
Date archived/stock date
Cell line repository/bank
Ethical/GMO work approvals

Serum-free and feeder-free medium
Induced mutation
DYT1 dystonia
TOR1A c.907_909delGAG (p.Glu303del)/
9q34.11
Isogenic clones carrying heterozygous or
homozygous of the same gene mutation.
CRISPR/Cas9
Electroporated with a 4D-Nucleofector
(Lonza) using CA-137 program.
gRNA vector MLM3636 (Addgene #43860)
Cas9 vector p3s-Cas9HC (Addgene #43945)
(continued on next column)

Addgene/public access repository
recombinant DNA sources’
disclaimers (if applicable)

ULLi002-A-49
ULLi002-A-51
Sequencing of the targeted allele
Targeted PCR/sequencing
N/A
N/A
N/A
4/29/2021
https://hpscreg.eu/cell-line/ULLi002-A-49
https://hpscreg.eu/cell-line/ULLi002-A-51
Genetic modification was performed at
Genome Engineering and iPSC Center
(GEiC) at Washington University in St. Louis.
N/A

2. Resource utility
Although rodent models of DYT1 dystonia provide insights into
disease mechanisms, significant species-dependent differences exist
because animals with the identical heterozygous mutation fail to show
pathology. These hiPSC lines will provide a valuable resource to develop
human cellular systems in modeling DYT1 dystonia. Table 1
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3. Resource details

contain heterozygous (ULLi002-A-49) and homozygous (ULLi002-A-51)
GAG deletion (c.907–909) in the TOR1A gene. Chromosomes from iPSCs
were harvested and analyzed using the GTW banding method. Of 20
metaphase cells examined of each clone, all cells are characteristic of a
chromosomally normal male karyotype, 46, XY (Fig. 1C). Short tandem
repeat (STR) analysis at 18 loci indicated that ULLi002-A-49 and
ULLi002-A-51 clones completely matched the parental hiPSC
(UCSFi001-A) identity (Supp. Fig. S1C). Immunostaining indicated that
these iPSCs highly expressed pluripotency markers of OCT4, NANOG,
SOX2, and SSEA4 (Fig. 1D). Quantitative RT-PCR analysis demonstrated
that the pluripotency markers of OCT4, SOX2, NANOG, and KLF4 were
expressed at similar levels as their parental line (UCSFi001A) (Fig. 1F).
Following spontaneous differentiation, embryoid bodies (EBs) (Fig. 1E)
derived from ULLi002-A-49 and ULLi002-A-51 displayed dramatic
upregulation of markers of the ectoderm (PAX6, OTX1), mesoderm
(DCN, IGF2, GATA2) and endoderm (SOX7, SOX17) lineages. The
expression levels of these trilineage markers were consistent with their
parental line UCSFi001-A and much higher than undifferentiated iPSCs
(Fig. 1G). PCR screening demonstrated that ULLi002-A-49 and ULLi002A-51 were negative for mycoplasma (Fig. S1 D).

Dystonia is a common movement disorder characterized by sus
tained or intermittent muscle contractions causing abnormal move
ments and/or postures. Because the clinical characteristics and
underlying causes of dystonia are very heterogeneous, the pathological
mechanisms of dystonia remain largely unknown (Ding, 2022). The
diagnosis and etiological definition of this disorder remain challenging.
The childhood-onset DYT1 dystonia represents the most frequent and
severe form of dystonia, providing an excellent example to understand
the pathogenesis of this disease. The typical DYT1 dystonia is caused by
a heterozygous GAG deletion (c.907–909) in the TOR1A gene (ΔE, p.
Glu303del) (Ozelius et al., 1997). Interestingly, mice with the identical
Tor1a mutation as a heterozygote failed to show any pathological phe
notypes (Goodchild et al., 2005), suggesting that the significant speciesdependent differences exist between DYT1 mouse models and human
patients. However, the limited access to patient neurons and the lack of
in vitro human neuronal systems greatly impede the progress of research
in dystonia. Generation of hiPSC lines containing disease-causing mu
tations and their isogenic controls has been shown to be a powerful tool
in modeling human neurological diseases (Sepehrimanesh and Ding,
2020; Ding et al., 2021). In this study, we genetically modified a wellcharacterized hiPSC line (WTC11, UCSFi001-A) with CRISPR/Cas9
method and obtained two iPSC clones carrying the heterozygous
(ULLi002-A-49, or USCFi001-A-49) and homozygous (ULLi002-A-51, or
USCFi001-A-51) GAG deletion in the TOR1A gene, respectively. These
hiPSC lines and their isogenic controls provide a valuable resource in
modeling DYT1 dystonia.
Both lines showed a typical pluripotent stem cell morphology with a
high nucleus/cytoplasm ratio (Fig. 1A). Sanger DNA sequencing of po
lymerase chain reaction (PCR) products (Fig. 1B) and deep sequencing
analysis (Supp. Fig. S1A and S1B) confirmed that these iPSC lines

4. Materials and methods
4.1. Generate and culture TOR1A mutant iPSCs
Human TOR1A mutant clones were generated from the WTC11 iPSC
line (Gladstone institute, UCSFi001-A) by the Genome Engineering and
iPSC center (GEiC) at Washington University in St. Louis. Briefly,
approximately 1×106 single cells were resuspended in P3 primary buffer
(Lonza) with gRNA/Cas9 ribonucleoprotein (RNP) complex (200 pmol
synthetic gRNA and 80 pmol SpCas9 protein) and hTOR1A mutant
single-stranded oligo donor (ssODN) (Table 2). Subsequently, cells were

Table 1
Characterization and validation.
Classification

Test

Result

Data

Morphology
Pluripotency status evidence for
the described cell line

Photography
Qualitative analysis

Fig. 1 Panel A
Fig. 1 Panel D

Karyotype

Karyotype (G-banding) and
resolution
PCR across the edited site and deep
sequencing analysis

Typical primed pluripotent human stem cell morphology.
Immunocytochemistry showed expression of pluripotency markers:
OCT4, SOX2, NANOG, SSEA4.
Compared to DAPI, % of positive cell (ULLi002-A-49, ULLi002-A-51)
OCT4: 98%, 98%; SOX2: 99%, 98%; NANOG: 97%, 95%; SSEA-4: 97%,
98%. RT-PCR showed highly express OCT4, SOX2, NANOG, KLF4.
46, XY, Resolution 400
Heterozygous or homozygous GAG deletion (c.907–909) in TOR1A
gene.

Fig. 1 Panel B and
Supplementary Fig. S1A
and B.
N/A
N/A

Genotyping for the desired
genomic alteration/allelic status
of the gene of interest
Verification of the absence of
random plasmid integration
events
Parental and modified cell line
genetic identity evidence
Mutagenesis/genetic modification
outcome analysis

Off-target nuclease analysis
Specific pathogen-free status
Multilineage differentiation
potential
Donor screening (OPTIONAL)
Genotype additional info
(OPTIONAL)

Quantitative analysis

Fig. 1 Panel D and F
Fig. 1 Panel C

Transgene-specific PCR
PCR/Southern

N/A
Off Target Analysis of gRNA showed 100% minus a weighted sum of offtarget hit-scores in the target genome.

STR analysis, microsatellite PCR
(mPCR) or specific (mutant) allele
seq
Sequencing (genomic DNA PCR or
RT-PCR product)

STR analysis of 18 loci, all matched.

Supplementary Fig. S1C

The sequencing results of genomic DNA all matched with the parental
line.

PCR-based analyses

The sequencing results PCR products all matched with the parental line.

Southern Blot or WGS; western
blotting (for knock-outs, KOs)
PCR across top 5/10 predicted top
likely off-target sites, whole genome/
exome sequencing
Mycoplasma
Embryoid body formation, RT-PCR

N/A

Fig. 1 Panel B and
Supplementary Fig. S1A
and B
Fig. 1 Panel B and
Supplementary Fig. S1A
and B
N/A

N/A

N/A

Tested by MycoAlert PLUS kit: Negative
Upregulation of trilineage markers PAX6, OTX1 (ectoderm), DCN, IGF2,
GATA2 (mesoderm), and SOX7, SOX17 (endoderm).
N/A
N/A
N/A

Fig. S1D
Fig. 1 Panel G

HIV 1 + 2 Hepatitis B, Hepatitis C
Blood group genotyping
HLA tissue typing

2

N/A
N/A
N/A
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Fig. 1. Characterization of ULLi002-A49 and ULLi002-A51 iPSC lines.

electroporated with a 4D-Nucleofector (Lonza) using CA-137 program.
Following nucleofection, the editing efficiency was confirmed by tar
geted deep sequencing using primer sets specific to target regions, and
then the pool was single-cell sorted. Single cell clones were screened
with targeted deep sequencing analysis. All iPSCs were cultured with
mTeSR Plus (STEMCELL Technology) on matrigel-coated plates at 37 ◦ C
in a humidified, 5% CO2 incubator and passage at a 1:6 ratio using
gentle cell dissociation reagent (Versene, Gibco).

markers) or without (for cell surface marker SSEA4) 0.2% Triton X-100
for 1 h. Cells were then incubated with primary antibodies (Table 2) in
blocking buffer at 4 ◦ C overnight and then followed by washing and
incubation with fluorophore-conjugated corresponding secondary anti
bodies at room temperature for 2 hrs. Nuclei were stained with Hoechst
33342 (Invitrogen). Images were obtained with a Leica SP5 confocal
microscope.
4.4. Quantitative PCR analysis

4.2. Embryoid bodies (EB) formation

iPSCs and EBs were collected from cultured plates and lysed in
TRIzol (Invitrogen). Total RNAs were isolated by the phenol/chloroform
extracting method, and then were reverse-transcribed into cDNAs with
the SuperScript™ III Reverse Transcriptase (Invitrogen). Quantitative
PCR analysis was performed using SYBR Green PCR Master Mix (Applied
Biosystems) and run on StepOne qPCR machine (Applied Biosystems).
The gene expression data were analyzed using the ΔΔCT method and the
values were normalized to the expression of the GAPDH housekeeping
gene (Fig. 1F and G). Primers used in this study were listed in Table 2.

hiPSCs were dissociated with Versene and transferred to low
attachment 10-cm petri dishes in KOSR medium (DMEM/F12 medium
containing 20% KnockOut Serum Replacement, 1% GlutaMax, 1% nonessential amino acids, 50 μM β-mercaptoethanol, and 1% pen
icillin–streptomycin) supplemented with 10 µM Y-27632. The medium
was changed every other day and EBs gradually formed. After 7 days of
suspension culture, EBs were digested with 0.25% Trypsin and cultured
on gelatin coated plates with KOSR medium for another 7 days. The total
RNAs were extracted for RT-PCR analysis.

4.5. Karyotyping

4.3. Immunostaining and confocal microscopy

Chromosomes from iPSC clones were analyzed using the GTW
banding method at GEiC at Washington University in St. Louis.

Briefly, cultured iPSCs were fixed with 4% paraformaldehyde (PFA)
in PBS for 15 min at room temperature followed by incubation in
blocking buffer (3% bovine serum albumin in PBS) with (for nuclear
3
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Table 2
Reagents details.
Antibodies used for immunocytochemistry
Antibody

Dilution

Company Cat # and RRID

Nuclear stain

Mouse anti-OCT4
Mouse anti-SOX2
Mouse anti-SSEA4
Rabbit anti-Nanog
Donkey anti-Mouse IgG (H + L), Alexa Fluor 488
Donkey Anti-Rabbit IgG (H + L), Alexa Fluor 594
Hoechst33342

1:200
1:200
1:200
1:100
1:500
1:500
1 µg/mL

Santa Cruz Cat# sc-5279, RRID: AB_628051
Santa Cruz Biotechnology Cat# sc-365823, RRID:AB_10842165
Abcam Cat# ab16287, RRID:AB_778073
Abcam Cat# ab21624, RRID:AB_446437
Jackson ImmunoResearch Labs Cat# 715-545-150, RRID:AB_2340846
Jackson ImmunoResearch Labs Cat# 711-585-152, RRID:AB_2340621
Invitrogen Cat # H3570. RRID: NOT FOUND

Site-specific nuclease
Nuclease information
Delivery method
Selection/enrichment strategy

Cas9
electroporation
sorted into 96-well plates with one cell per well

Cas9 vector p3s-Cas9HC (Addgene #43945)
4D-Nucleofector (Lonza, Cat # AAF-1002B)
Single cell clones were screened and expanded

Pluripotency Markers

Secondary antibodies

Primers and Oligonucleotides used in this study
Target
Pluripotency marker
OCT 3/4
Pluripotency marker
SOX 2
Pluripotency marker
NANOG
Pluripotency marker
KLF4
Differentiation marker
PAX6
Differentiation marker
OTX1
Differentiation marker
DCN
Differentiation marker
IGF2
Differentiation marker
GATA2
Differentiation marker
SOX7
Differentiation marker
SOX17
House-Keeping Genes
GAPDH
Genotyping-PCR
TOR1A
Sequencing
TOR1A
hTOR1A gRNA (IDT)
TOR1A
hTOR1A ssODN (IDT)
TOR1A

Forward/Reverse primer (5′ -3′ )
CGAGAGGATTTTGAGGCTGC/CGAGGAGTACAGTGCAGTGA
AGGATAAGTACACGCTGCCC/TTCATGTGCGCGTAACTGTC
TGTCTTCTGCTGAGATGCCT/CAGAAGTGGGTTGTTTGCCT
TCTCCAATTCGCTGACCCAT/CGGATCGGATAGGTGAAGCT
GGGCGGAGTTATGATACCTACA/ATATCAGGTTCACTTCCGGGAA
TACGCCCTCCTCTTCCTACT/GCATGTGGGTGGTGATGATG
CTGAAGAACCTTCACGCATTGA/GGCAATTCCTTCAGCTGATTCT
CAATATGACACCTGGAAGCAGT/GTAGAGCAATCAGGGGACGG
ACCTGTTGTGCAAATTGTCAGA/ATCCCTTCCTTCTTCATGGTCA
ACTCCACTCCAACCTCCAAG/TTCATTGCGATCCATGTCCC
ATCGGGGACATGAAGGTGAA/TCCTTAGCCCACACCATGAA
CAAATTCCATGGCACCGTCA/GGACTCCACGACGTACTCAG
ACAGCAGCTTAATTGACCGGA/ATCATGAGCCCTGCGATGAG
GTGTATCCGAGTGGAAATGC
TGAAGACATTGTAAGCAGAG
AATGTGTATCCGAGTGGAAATGCAGTCCCGAGGCTATGAAATT
GATGAAGACATTGTAAGTAGAGTGGCTGAGATGACATTTTTCC
CCAAAGAGGAGAGAGTTTTCTCAGATAAAGGCTGCA

4.6. STR analysis

Stroke (No. NIH/NINDS NS112910 to B.D.) and Department of Defense
(DoD) Peer Reviewed Medical Research Program (PRMRP) Discovery
Award (No. W81XWH2010186 to B.D.).

Short tandem repeat (STR) analysis of 18 loci (Fig. S1C) were per
formed at GEiC at Washington University in St. Louis.

Appendix A. Supplementary data

4.7. Mycoplasma test

Supplementary data to this article can be found online at https://doi.
org/10.1016/j.scr.2021.102536.

Mycoplasma test (Fig. S1D) was performed by MycoAlert PLUS kit
(Lonza) at GEiC at Washington University in St. Louis.
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